Transcode Therapeutics (RNAZ) Prepaid Assets (2020 - 2026)
Transcode Therapeutics' (RNAZ) quarterly Prepaid Assets came in at $1.0 million in Q1 2026, down 11.76% YoY from $1.2 million in Q1 2025, and up 255.59% on a QoQ basis from $286064.0 in Q4 2025.
Transcode Therapeutics (RNAZ) Prepaid Assets (2020 - 2026) Analysis & Trends
Transcode Therapeutics (RNAZ) has 7 years of Prepaid Assets data on file, last reported at $1.0 million in Q1 2026.
- Quarterly Prepaid Assets fell 11.76% year-over-year to $1.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.0 million (down 11.76% YoY) and the FY2025 annual result came in at $286064.0, down 7.94% from the prior year.
- Prepaid Assets rose to $1.0 million in Q1 2026, from $286064.0 in the prior quarter.
- In the past five years, Prepaid Assets ranged from a high of $1.7 million in Q3 2024 to a low of $18149.0 in Q3 2025.
- A 5-year average of $600753.5 and a median of $286064.0 in 2025 frame the typical range for Prepaid Assets.
- Annual changes were most pronounced in 2024 — Prepaid Assets soared 2673.25% — and 2025, when it tumbled 98.95%.
- Tracing RNAZ's Prepaid Assets over 5 years: stood at $122428.0 in 2022, then soared by 1278.64% to $1.7 million in 2023, then sank by 81.59% to $310735.0 in 2024, then retreated by 7.94% to $286064.0 in 2025, then jumped by 255.59% to $1.0 million in 2026.
- The last three Prepaid Assets figures came in at $1.0 million (Q1 2026), $286064.0 (Q4 2025), and $18149.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Transcode Therapeutics | 2.84 Mn | 2.84 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.02 Mn |
| Dec 31, 2025 | 286,064.00 |
| Sep 30, 2025 | 18,149.00 |
| Jun 30, 2025 | 34,368.00 |
| Mar 31, 2025 | 1.15 Mn |
| Dec 31, 2024 | 310,735.00 |
| Sep 30, 2024 | 1.72 Mn |
| Jun 30, 2024 | 1.03 Mn |
| Mar 31, 2024 | 97,324.00 |
| Dec 31, 2023 | 1.69 Mn |
| Sep 30, 2023 | 658,188.00 |
| Jun 30, 2023 | 37,208.00 |
| Mar 31, 2023 | 1.51 Mn |
| Dec 31, 2022 | 122,428.00 |
| Sep 30, 2022 | 172,652.00 |
| Jun 30, 2022 | 260,387.00 |
| Mar 31, 2022 | 92,525.00 |
| Dec 31, 2021 | 1.39 Mn |
| Sep 30, 2021 | 2.70 Mn |
| Jun 30, 2021 | 460,652.00 |